Outlook Therapeutics
OTLK
88 hedge funds and large institutions have $51.4M invested in Outlook Therapeutics in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 7 closing their positions.
165% more capital inflows, than outflows
Capital inflows: $4.73M | Capital outflows: $1.79M
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
6% more funds holding
Funds holding: 83 → 88 (+5)
0.8% more ownership
Funds ownership: 10.7% → 11.5% (+0.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.57M |
| 2 |
State Street
Boston,
Massachusetts
|
+$998K |
| 3 |
Squarepoint
New York
|
+$343K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$250K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$507K |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$350K |
| 3 |
Vista Finance
Clayton,
Missouri
|
-$237K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
-$107K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$98.8K |
OTLK Hedge Fund Activity: Q2 2023 in Review
88 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2023, worth a combined $51.4M — up 72% from $29.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OTLK positions and 7 closed out — a net gain of 5 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $1.57M. The largest seller was Millennium Management, cutting an estimated $507K.
- 88 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2023, up from 83 in Q1 2023.
- Funds reported $51.4M of Outlook Therapeutics stock for Q2 2023, up 72% quarter-over-quarter.
- 12 funds opened new Outlook Therapeutics positions in Q2 2023 and 7 closed out, a net change of +5 holders.
- The largest Outlook Therapeutics buyer in Q2 2023 was BlackRock, an estimated $1.57M added.
- The largest Outlook Therapeutics seller in Q2 2023 was Millennium Management, an estimated $507K sold.
Based on aggregated 13F filings for Q2 2023.